Gilman Hill Asset Management LLC decreased its stake in shares of Merck & Co. (NYSE:MRK) by 5.7% during the second quarter, Holdings Channel reports. The fund owned 15,302 shares of the company’s stock after selling 925 shares during the period. Gilman Hill Asset Management LLC’s holdings in Merck & Co. were worth $882,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Orbis Allan Gray Ltd acquired a new stake in shares of Merck & Co. during the first quarter valued at approximately $239,761,000. NN Investment Partners Holdings N.V. acquired a new stake in shares of Merck & Co. during the first quarter valued at approximately $174,068,000. Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Merck & Co. by 249.7% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,288,444 shares of the company’s stock valued at $121,082,000 after buying an additional 1,634,004 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Merck & Co. during the first quarter valued at approximately $67,685,000. Finally, Canada Pension Plan Investment Board raised its stake in shares of Merck & Co. by 326.5% in the first quarter. Canada Pension Plan Investment Board now owns 1,626,461 shares of the company’s stock valued at $86,056,000 after buying an additional 1,245,129 shares during the last quarter. Institutional investors own 72.93% of the company’s stock.
Shares of Merck & Co. (NYSE:MRK) traded up 0.81% during trading on Friday, reaching $62.41. The company’s stock had a trading volume of 13,605,282 shares. The company has a market capitalization of $172.58 billion, a price-to-earnings ratio of 34.23 and a beta of 0.63. Merck & Co. has a one year low of $47.97 and a one year high of $64.00. The firm’s 50-day moving average price is $62.76 and its 200-day moving average price is $58.03.
Merck & Co. (NYSE:MRK) last posted its quarterly earnings data on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.02. The business had revenue of $9.84 billion for the quarter, compared to analysts’ expectations of $9.79 billion. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The business’s revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.86 EPS. On average, equities analysts anticipate that Merck & Co. will post $3.75 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be given a $0.46 dividend. The ex-dividend date of this dividend is Tuesday, September 13th. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.95%. Merck & Co.’s dividend payout ratio is currently 101.10%.
MRK has been the topic of several research analyst reports. Goldman Sachs Group Inc. restated a “neutral” rating and set a $60.00 target price on shares of Merck & Co. in a research report on Wednesday, June 8th. Citigroup Inc. restated a “neutral” rating and set a $65.00 target price on shares of Merck & Co. in a research report on Wednesday, August 10th. BMO Capital Markets upgraded Merck & Co. from a “market perform” rating to an “outperform” rating and upped their target price for the company from $62.00 to $72.00 in a research report on Friday, August 5th. Jefferies Group dropped their price target on Merck & Co. from $54.00 to $53.00 and set a “hold” rating on the stock in a research note on Tuesday, June 14th. Finally, Morgan Stanley set a $60.00 price target on Merck & Co. and gave the stock a “hold” rating in a research note on Tuesday, September 13th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company’s stock. Merck & Co. presently has a consensus rating of “Hold” and an average price target of €63.20 ($70.23).
In other news, EVP Clark Golestani sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of €63.03 ($70.03), for a total value of €189,090.00 ($210,100.00). The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Adam H. Schechter sold 39,200 shares of the business’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of €62.61 ($69.57), for a total value of €2,454,312.00 ($2,727,013.33). Following the completion of the sale, the executive vice president now directly owns 39,200 shares in the company, valued at €2,454,312 ($2,727,013.33). The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.